Novataris A/S company information, Employees & Contact Information

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline Novartis

Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) Novartis

Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024 Novartis

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer Novartis

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer Novartis

Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis Novartis

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Novartis

The 2025 Eurovision Song Contest Novartis

Our commitment to ethical and responsible use of Artificial Intelligence (AI) Novartis

Oncology research at Novartis Novartis

Immunology disease research at Novartis Novartis

Managed access programs Novartis

Targets Novartis

Payments to Healthcare Professionals Novartis

Human rights Novartis

FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS) Novartis

Therapeutic areas Novartis

Compassionate use: Providing access to much needed treatments Novartis

Coronavirus Novartis

Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline Novartis

From black holes to AI driven drug discovery – collaboration wins the day Novartis

Sub-Saharan Africa Novartis

FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis Novartis

About Novartis

US Biomedical Research internship programs Novartis

Novartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance Novartis

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN) Novartis

Board of Directors Novartis

FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer Novartis

Climate Novartis

Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH Novartis

Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML Novartis

Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2 Novartis

Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA Novartis

Novartis bolsters innovative medicines strategy and renal pipeline with agreement to acquire Chinook Therapeutics for USD 3.2bn upfront (USD 40 / share) Novartis

ESG rating performance Novartis

Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors Novartis

Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials Novartis

Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G) Novartis

Novartis data show rapid and effective disease activity control with remibrutinib (LOU064) in patients with chronic spontaneous urticaria Novartis

Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria Novartis

Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death Novartis

Novartis announces lift of partial clinical trial hold and plans to initiate a new, pivotal Phase 3 study of intrathecal OAV-101 in older patients with SMA Novartis

Novartis acquires Arctos Medical, expanding optogenetics portfolio to bring gene therapies to patients with severe vision loss Novartis

Novartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grade gliomas in Phase II/III study Novartis

Novartis receives European Commission approval for Pluvicto® as the first targeted radioligand therapy for treatment of progressive PSMA–positive metastatic castration-resistant prostate cancer Novartis

Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19 Novartis

Novartis to sell its Roche stake in a bilateral transaction to Roche Novartis

Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis Novartis

AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families Novartis

Novartis provides update on production of radioligand therapy medicines Novartis

Novartis expands Zolgensma manufacturing capacity with approval of multi-product North Carolina facility Novartis

Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer Novartis

Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer Novartis

Novartis receives EU approval for Leqvio®* (inclisiran), a first-in-class siRNA to lower cholesterol with two doses a year Novartis

European Medicines Agency (EMA) approves safety label update for Novartis Beovu® Novartis

Novartis announces collaboration on HARMONIA, a Phase III, head-to-head trial evaluating Kisqali® vs. Ibrance®* in patients with HR+/HER2- advanced breast cancer Novartis

Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19 Novartis

Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene Novartis

World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio® ▼(inclisiran) Novartis

Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease Novartis

Novartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU) Novartis

Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice Novartis

Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond Novartis

Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence Novartis

Novartis expands Africa Sickle Cell Disease program to Uganda and Tanzania Novartis

Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader Novartis

Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis Novartis

Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review Novartis

Novartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis Novartis

Novartis successfully completes acquisition of AveXis, Inc. Novartis

Novartis, Amgen and Banner Alzheimer's Institute discontinue clinical program with BACE inhibitor CNP520 for Alzheimer's prevention Novartis

Novartis announces completion of transactions with GSK Novartis

Novartis receives approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma® the only gene therapy for patients with spinal muscular atrophy (SMA) Novartis

Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL Novartis

Novartis expands Kymriah® manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia Novartis

Novartis received European Medicines Agency (EMA) PRIME designation for iptacopan (LNP) in C3 glomerulopathy (C3G) Novartis

Novartis Cosentyx® gains fourth indication in EU with first-in-class approval in axial spondyloarthritis spectrum Novartis